Steven Cohen Zai Lab LTD Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Zai Lab LTD stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 13,464 shares of ZLAB stock, worth $359,758. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,464

Holding current value

$359,758

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$16.25 - $24.14 $218,790 - $325,020	13,464 New	13,464 $325,000
Q1 2022 May 16, 2022	SELL	$27.77 - $64.4 $3.31 Million - $7.68 Million	-119,200 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$54.9 - $105.21 $6.54 Million - $12.5 Million	119,200 New	119,200 $7.49 Million
Q3 2020 Nov 16, 2020	SELL	$73.3 - $89.48 $79,897 - $97,533	-1,090 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$48.82 - $82.53 $53,213 - $89,957	1,090 New	1,090 $90,000
Q4 2019 Feb 14, 2020	SELL	$29.79 - $43.06 $519,537 - $750,966	-17,440 Closed	0 $0
Q3 2019 Nov 15, 2019	BUY	$30.47 - $37.65 $531,396 - $656,616	17,440 New	17,440 $564,000
Q2 2019 Aug 14, 2019	SELL	$25.73 - $35.79 $1.36 Million - $1.9 Million	-53,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$21.71 - $31.54 $1.15 Million - $1.67 Million	53,000 New	53,000 $1.56 Million
Q4 2018 Feb 14, 2019	SELL	$14.95 - $24.72 $747,500 - $1.24 Million	-50,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$17.8 - $25.35 $890,000 - $1.27 Million	50,000 New	50,000 $974,000
Q4 2017 Feb 14, 2018	SELL	$21.23 - $34.09 $106,150 - $170,450	-5,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$27.0 - $31.11 $135,000 - $155,550	5,000	5,000 $135,000

Others Institutions Holding ZLAB

# of Institutions

121

Shares Held

46.7M

Call Options Held

223K

Put Options Held

588K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.62B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account